. Author manuscript; available in PMC: 2015 Sep 11.

Published in final edited form as: Cancer. 2015 Apr 22;121(15):2603–2611. doi: 10.1002/cncr.29398

Table 4.

Testosterone recovery.

	Median Testosterone (ng/dL) (Q1–Q3)	Testosterone ≥100 ng/dL N (%) (95% CI)	Testosterone ≥240 ng/dL N (%) (95% CI)
Baseline (n=41)^*	300.0 (255.0–394.0)	41(100%) (91–100)	33(81%) (65–91)
At completion of docetaxel (n=36)^*	10.5 (7.0–14.3)	0(0%) (0–10)	0(0%) (0–10)
At completion of ADT (n=35)^*	11.0 (7.5–27.5)	5(14%) (5–30)	3(9%) (2–23)
1 year after completion of ADT (n=35)^*	239.0 (145.0–345.0)	29(83%) (66–93)	17(49%) (31–66)

n reflects patients for which testosterone data was available at the specified time point.